Bristol-Myers Squibb stock falls after positive CAR T trial data

Published on 09/09/2026 at 12:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock slipped after the company reported positive Phase 2 results for its arlo-cel CAR T therapy on September 8, 2026. The shares trade above intrinsic value estimates while offering a dividend yield near 3.8 percent.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb stock (ISIN US1078421011) is trading below recent highs even after the company announced positive Phase 2 trial results for its experimental CAR T cell therapy arlocabtagene autoleucel, or arlo-cel, on September 8, 2026. According to Benzinga, the shares were down 2.51% to USD 65.14 during trading on September 8, 2026, despite the encouraging clinical data.

Arlo-cel delivers strong Phase 2 results

As Benzinga reports, Bristol-Myers Squibb on September 8, 2026 shared outcomes from the registrational QUINTESSENTIAL Phase 2 study of arlo-cel in adult patients with relapsed and refractory multiple myeloma who were exposed to at least four prior classes of therapy. The trial met its primary endpoint, delivering a statistically significant and clinically meaningful overall response rate in patients who had received four or more prior lines of treatment.

The company also achieved key secondary endpoints in the same study. According to Benzinga, arlo-cel produced a successful complete response rate for patients with four or more prior lines of therapy and also met overall response rate and complete response rate objectives in patients who had received at least three previous treatments. Trial investigators described the safety profile as consistent with other CAR T cell therapies and with existing GPRC5D-targeted options used to treat multiple myeloma.

Therapy design and strategic significance

Arlo-cel is described as an autologous GPRC5D-directed CAR T cell therapy that is designed to be administered as a single infusion, potentially offering a differentiated approach for heavily pretreated multiple myeloma patients. The treatment process, as outlined by Benzinga, involves collecting T cells from the patient, administering bridging therapy, manufacturing the modified CAR T cells, applying lymphodepleting chemotherapy and then delivering the single infusion, followed by monitoring.

From an investor perspective, the positive Phase 2 data strengthens Bristol-Myers Squibb's immuno-oncology pipeline and supports its long-term growth narrative in oncology. A detailed valuation analysis from GuruFocus on September 8, 2026 highlights that Bristol-Myers Squibb generates roughly 70% of its sales in the United States and has a market capitalization of USD 136.49 billion, underscoring its scale in the global drug manufacturers industry.

Dividend yield and valuation comparison

The same GuruFocus analysis indicates that Bristol-Myers Squibb offers a dividend yield of 3.76% with a payout ratio of 39%, supported by a three-year dividend growth rate of 4.4% as of the assessment dated September 8, 2026. According to GuruFocus, its proprietary GF Value model estimates an intrinsic value of USD 56.54 per share for Bristol-Myers Squibb, while the stock was trading at USD 66.82 at the time of the report. That implies the shares were approximately 18.2% above the GF Value estimate, a quantified premium that suggests modest overvaluation on that metric.

Beyond the GF Value measure, the stock trades at a trailing price-earnings ratio of 14.72, which is below its five-year median P/E of 18.13 according to GuruFocus. For investors, this combination means the shares trade above one intrinsic-value estimate yet at a discount to their historical earnings multiple, while still offering a mid-single-digit dividend yield with room for continued growth.

Profitability metrics and financial strength

The GuruFocus GF Score framework, which aggregates financial strength, profitability, growth, valuation and momentum, assigns Bristol-Myers Squibb a score of 71 out of 100 as of September 8, 2026. According to GuruFocus, the company scores 8 out of 10 on profitability, supported by operating margins of 28.14% and net margins of 18.87%, both above typical industry medians.

On financial strength, Bristol-Myers Squibb scores a more moderate 5 out of 10, reflecting factors such as a debt-to-equity ratio of 2.02 and an Altman Z-Score of 2.79, which lies in the so-called grey zone indicating some balance-sheet leverage but no immediate distress. Growth receives a 4 out of 10 in the GF Score, consistent with the company’s classification as a slow-growth name and with recent earnings pressures, while valuation and momentum scores are middling at 6 and 3 out of 10 respectively. For investors, this profile suggests strong profitability and an attractive dividend, offset by modest growth and a leveraged capital structure.

Institutional and insider activity as a risk factor

Institutional and insider behavior provides another lens on Bristol-Myers Squibb stock. GuruFocus notes that 16 so-called premium gurus hold positions in the company, with six adding to their stakes and 12 trimming holdings in recent quarters. According to GuruFocus, insider activity shows no insider share purchases over the past year, while insider selling totals about USD 1.9 million.

This pattern of net trimming by institutional investors and net insider selling, alongside the roughly 18.2% premium to the GF Value estimate, represents a tangible risk factor for shareholders. It suggests that while the company’s pipeline and dividend are attractive, some professional investors are cautious about upside potential from current levels and are selectively reducing exposure. For retail investors, monitoring how future clinical milestones, including full QUINTESSENTIAL data presentations, interact with valuation and insider trends will be important.

Stock level and market context

Price data from the week around September 9, 2026 show Bristol-Myers Squibb stock trading in the mid-USD 60s on the New York Stock Exchange, with the Benzinga report citing a level of USD 65.14 on September 8, 2026 and GuruFocus describing a contemporaneous price of USD 66.82. Taken together, these figures indicate the shares are trading close to 18.2% above the GF Value estimate of USD 56.54 while still below the five-year median P/E multiple when measured against current earnings. With a market capitalization of USD 136.49 billion and a dividend yield of 3.76% as of September 8, 2026, Bristol-Myers Squibb stock continues to offer income and exposure to oncology innovation, but at a valuation that already prices in a meaningful part of its near-term growth story.